| Year |
Citation |
Score |
| 2024 |
Mu R, Zhan X, Tang RS, Yuan Y. A Bayesian latent-subgroup platform design for dose optimization. Biometrics. 80. PMID 39253988 DOI: 10.1093/biomtc/ujae093 |
0.31 |
|
| 2024 |
Jiang L, Yin Z, Yan F, Yuan Y. MC-Keyboard: A Practical Phase I Trial Design for Targeted Therapies and Immunotherapies Integrating Multiple-Grade Toxicities. Journal of Immunotherapy and Precision Oncology. 7: 159-167. PMID 39219992 DOI: 10.36401/JIPO-23-35 |
0.325 |
|
| 2024 |
Ye J, Pan H, Reaman G, Roychoudhury S, Lu C, Renfro LA, Ji Y, Liu R, Yuan Y, Zhang W. Considerations on Design and Analysis of External Control in Pediatric Oncology. Medical Research Archives. 12. PMID 39026931 DOI: 10.18103/mra.v12i1.5088 |
0.574 |
|
| 2024 |
Yang P, Li D, Lin R, Huang B, Yuan Y. Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in Medicine. PMID 38747472 DOI: 10.1002/sim.10093 |
0.325 |
|
| 2024 |
Chi X, Yuan Y, Yu Z, Lin R. A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical Journal. Biometrische Zeitschrift. 66: e2300122. PMID 38368277 DOI: 10.1002/bimj.202300122 |
0.319 |
|
| 2024 |
Zang Y, Thall PF, Yuan Y. A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics. 80. PMID 38364811 DOI: 10.1093/biomtc/ujad022 |
0.301 |
|
| 2024 |
Yuan Y, Zhou H, Liu S. Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical Trials (London, England). 17407745231207085. PMID 38243399 DOI: 10.1177/17407745231207085 |
0.301 |
|
| 2023 |
Zhao Y, Yuan Y, Korn EL, Freidlin B. Backfilling Patients in Phase I Dose Escalation Trials Using Bayesian Optimal Interval Design (BOIN). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38048044 DOI: 10.1158/1078-0432.CCR-23-2585 |
0.326 |
|
| 2023 |
Zhang W, Laird G, Chen J, Yuan Y. A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints. Statistics in Medicine. PMID 37937591 DOI: 10.1002/sim.9948 |
0.335 |
|
| 2023 |
Thall PF, Zang Y, Chapple AG, Yuan Y, Lin R, Marin D, Msaouel P. Novel clinical trial designs with dose optimization to improve long-term outcomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37725573 DOI: 10.1158/1078-0432.CCR-23-2222 |
0.328 |
|
| 2023 |
Thall PF, Zang Y, Yuan Y. Generalized phase I-II designs to increase long term therapeutic success rate. Pharmaceutical Statistics. PMID 37038957 DOI: 10.1002/pst.2301 |
0.3 |
|
| 2022 |
Lin R, Shi H, Yin G, Thall PF, Yuan Y, Flowers CR. BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS. The Annals of Applied Statistics. 16: 2481-2504. PMID 36329718 DOI: 10.1214/22-aoas1600 |
0.325 |
|
| 2022 |
Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Statistics in Medicine. PMID 35098585 DOI: 10.1002/sim.9337 |
0.315 |
|
| 2021 |
Lin R, Thall PF, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Analysis. 16: 179-202. PMID 34267857 DOI: 10.1214/20-ba1205 |
0.312 |
|
| 2021 |
Jiang L, Li R, Yan F, Yap TA, Yuan Y. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemporary Clinical Trials. 106338. PMID 33711459 DOI: 10.1016/j.cct.2021.106338 |
0.314 |
|
| 2021 |
Shi H, Cao J, Yuan Y, Lin R. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials. Statistics in Medicine. PMID 33650708 DOI: 10.1002/sim.8922 |
0.317 |
|
| 2020 |
Atkins JT, George GC, Hess K, Marcelo-Lewis KL, Yuan Y, Borthakur G, Khozin S, LoRusso P, Hong DS. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. British Journal of Cancer. PMID 32868897 DOI: 10.1038/S41416-020-01033-X |
0.343 |
|
| 2020 |
Abi Jaoude J, Kouzy R, Minsky BD, Fuller CD, Yuan Y, Do KA, Taniguchi CM, Ludmir EB. Sponsor-Involved Statistical Analyses in Phase III Cancer Clinical Trials. International Journal of Cancer. PMID 32621758 DOI: 10.1002/Ijc.33180 |
0.49 |
|
| 2020 |
Zhou H, Chen C, Sun L, Yuan Y. Bayesian optimal phase II clinical trial design with time-to-event endpoint. Pharmaceutical Statistics. PMID 32524679 DOI: 10.1002/Pst.2030 |
0.391 |
|
| 2020 |
Pan H, Cheng C, Yuan Y. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction. Pharmaceutical Statistics. PMID 32248647 DOI: 10.1002/Pst.2013 |
0.651 |
|
| 2020 |
Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemporary Clinical Trials. 105972. PMID 32151751 DOI: 10.1016/J.Cct.2020.105972 |
0.653 |
|
| 2020 |
Li Y, Yuan Y. PA-CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials. Biometrics. PMID 31950483 DOI: 10.1111/Biom.13217 |
0.369 |
|
| 2020 |
Lin R, Thall PF, Yuan Y. A Phase I–II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes Bayesian Analysis. DOI: 10.1214/20-Ba1205 |
0.366 |
|
| 2020 |
Gunn GB, Ferrarotto R, Johnson FM, Bell D, Cardoso R, Johnson JM, Rubin ML, Yuan Y, Frank SJ, Fuller CD, Rosenthal DI, Kupferman ME, Goepfert R, Hessel AC, Hutcheson KA, et al. Prospective, longitudinal digital activity monitoring before and after treatment of low-risk oropharyngeal squamous cell carcinoma: A feasibility study. Journal of Clinical Oncology. 38: 6578-6578. DOI: 10.1200/Jco.2020.38.15_Suppl.6578 |
0.404 |
|
| 2020 |
Majd N, Lin HY, Yuan Y, Alfaro-Munoz K, Hunter K, Heimberger AB, Groot JFD. Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab. Journal of Clinical Oncology. 38: 2559-2559. DOI: 10.1200/Jco.2020.38.15_Suppl.2559 |
0.347 |
|
| 2020 |
Yuan Y, Lin R, Li D, Nie L, Warren K. Abstract A21: Time-to-event Bayesian optimal interval design to accelerate phase I pediatric oncology trials Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-A21 |
0.424 |
|
| 2020 |
Zhou Y, Li R, Yan F, Lee JJ, Yuan Y. A Comparative Study of Bayesian Optimal Interval (BOIN) Design With Interval 3 + 3 (i3 + 3) Design for Phase I Oncology Dose-Finding Trials Statistics in Biopharmaceutical Research. 1-9. DOI: 10.1080/19466315.2020.1811147 |
0.391 |
|
| 2019 |
Zhou Y, Lee JJ, Yuan Y. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Statistics in Medicine. PMID 31621952 DOI: 10.1002/Sim.8361 |
0.401 |
|
| 2019 |
Tidwell RSS, Peng SA, Chen M, Liu DD, Yuan Y, Lee JJ. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clinical Trials (London, England). 1740774519871471. PMID 31450957 DOI: 10.1177/1740774519871471 |
0.35 |
|
| 2019 |
Lin R, Thall PF, Yuan Y. An Adaptive Trial Design to Optimize Dose--Schedule Regimes with Delayed Outcomes. Biometrics. PMID 31273750 DOI: 10.1111/Biom.13116 |
0.422 |
|
| 2019 |
Lin R, Yuan Y. On the relative efficiency of model-assisted designs: a conditional approach. Journal of Biopharmaceutical Statistics. 1-15. PMID 31258039 DOI: 10.1080/10543406.2019.1632881 |
0.4 |
|
| 2019 |
Lin R, Yuan Y. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics (Oxford, England). PMID 30984972 DOI: 10.1093/Biostatistics/Kxz007 |
0.435 |
|
| 2019 |
Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. European Journal of Cancer (Oxford, England : 1990). 112: 83-93. PMID 30951926 DOI: 10.1016/J.Ejca.2019.02.007 |
0.347 |
|
| 2019 |
Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. Journal of the National Cancer Institute. PMID 30924863 DOI: 10.1093/Jnci/Djz049 |
0.382 |
|
| 2019 |
Wu J, Yuan Y, Cordova C, Aboud O, Penas-Prado M, Theeler BJ, Bryla C, Su Y, Grajkowska E, McCoy A, Boris L, Siegel C, Antony R, Garren N, Lawhon T, et al. Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults. Journal of Clinical Oncology. 37: 2031-2031. DOI: 10.1200/Jco.2019.37.15_Suppl.2031 |
0.363 |
|
| 2019 |
Wages NA, Yuan Y. Preface to the themed issue on ‘Early phase clinical trial design methodology’ Journal of the Royal Statistical Society Series C-Applied Statistics. 68: 267-269. DOI: 10.1111/Rssc.12329 |
0.352 |
|
| 2019 |
Yust-Katz S, Donthireddy V, Mandel J, Abunafeesa H, Patil N, Yadav D, Jabbour-Aida H, Wu J, Yuan Y, Tsavachidis S, Walbert T, Bondy M, Armstrong T. QOLP-30. CLINICAL PREDICTIVE MODEL FOR THE DEVELOPMENT OF VENOUS THROMBOEMBOLISM IN GLIOBLASTOMA Neuro-Oncology. 21: vi204-vi204. DOI: 10.1093/Neuonc/Noz175.850 |
0.309 |
|
| 2019 |
Wu J, Bryla C, Su Y, Grajkowska E, McCoy A, Boris L, Antony R, Garren N, Siegel C, Cordova C, Aboud O, Vera E, Lawhon T, Penas-Prado M, Theeler B, ... ... Yuan Y, et al. ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS Neuro-Oncology. 21: vi27-vi28. DOI: 10.1093/Neuonc/Noz175.104 |
0.351 |
|
| 2019 |
Gross N, Ferrarotto R, Nagarajan P, Bell D, El-Naggar A, Johnson J, Yuan Y, Glisson B, Wong M, Rosenthal D, Esmaeli B, Migden M, Wargo J, Weber R, Myers J. Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN) Annals of Oncology. 30: v910. DOI: 10.1093/Annonc/Mdz394.071 |
0.317 |
|
| 2018 |
Liu S, Guo B, Yuan Y. A Bayesian Phase I/II Trial Design for Immunotherapy. Journal of the American Statistical Association. 113: 1016-1027. PMID 31741544 DOI: 10.1080/01621459.2017.1383260 |
0.424 |
|
| 2018 |
Tang R, Shen J, Yuan Y. ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage. Statistics in Medicine. PMID 30419609 DOI: 10.1002/Sim.8026 |
0.353 |
|
| 2018 |
Bahig H, Yuan Y, Mohamed ASR, Brock KK, Ng SP, Wang J, Ding Y, Hutcheson K, McCulloch M, Balter PA, Lai SY, Al-Mamgani A, Sonke JJ, van der Heide UA, Nutting C, et al. Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clinical and Translational Radiation Oncology. 13: 19-23. PMID 30386824 DOI: 10.1016/J.Ctro.2018.08.003 |
0.505 |
|
| 2018 |
Zhou H, Yuan Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Designs-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 5483-5484. PMID 30385656 DOI: 10.1158/1078-0432.Ccr-18-2677 |
0.352 |
|
| 2018 |
Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, et al. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. Bmc Cancer. 18: 903. PMID 30231854 DOI: 10.1186/S12885-018-4808-5 |
0.427 |
|
| 2018 |
Guo B, Li D, Yuan Y. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials. Pharmaceutical Statistics. PMID 29882388 DOI: 10.1002/Pst.1869 |
0.416 |
|
| 2018 |
Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, et al. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro-Oncology. PMID 29788429 DOI: 10.1093/Neuonc/Noy056 |
0.317 |
|
| 2018 |
Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29769209 DOI: 10.1158/1078-0432.Ccr-18-0246 |
0.424 |
|
| 2018 |
Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Statistics in Medicine. PMID 29682777 DOI: 10.1002/Sim.7674 |
0.656 |
|
| 2018 |
Zhou H, Yuan Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29661774 DOI: 10.1158/1078-0432.Ccr-18-0168 |
0.439 |
|
| 2018 |
Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. Bmc Medical Research Methodology. 18: 32. PMID 29580203 DOI: 10.1186/S12874-018-0473-2 |
0.573 |
|
| 2018 |
Chu Y, Yuan Y. A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clinical Trials (London, England). 1740774518755122. PMID 29499621 DOI: 10.1177/1740774518755122 |
0.376 |
|
| 2018 |
Murray TA, Yuan Y, Thall PF, Elizondo JH, Hofstetter WL. A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics. PMID 29359314 DOI: 10.1111/Biom.12842 |
0.403 |
|
| 2018 |
Msaouel P, Thall PF, Yuan Y, Chen I, Tannir NM. A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps708 |
0.333 |
|
| 2018 |
Ursino M, Yuan Y, Alberti C, Comets E, Favrais G, Friede T, Lentz F, Stallard N, Zohar S. A dose finding design for seizure reduction in neonates Journal of the Royal Statistical Society: Series C (Applied Statistics). 68: 427-444. DOI: 10.1111/Rssc.12289 |
0.389 |
|
| 2018 |
Mu R, Yuan Y, Xu J, Mandrekar SJ, Yin J. gBOIN: a unified model‐assisted phase I trial design accounting for toxicity grades, and binary or continuous end points Journal of the Royal Statistical Society: Series C (Applied Statistics). 68: 289-308. DOI: 10.1111/Rssc.12263 |
0.398 |
|
| 2018 |
Chu Y, Yuan Y. BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity Journal of the Royal Statistical Society Series C-Applied Statistics. 67: 723-740. DOI: 10.1111/Rssc.12255 |
0.363 |
|
| 2018 |
Armstrong T, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Gilbert M. RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB Neuro-Oncology. 20: vi241-vi241. DOI: 10.1093/Neuonc/Noy148.998 |
0.321 |
|
| 2018 |
Puduvalli V, Wu J, Yuan Y, Armstrong T, Wu J, Giglio P, Xu J, Colman H, Walbert T, Raizer J, Groves M, Iwamoto F, Tran D, Avgeropoulos N, Paleologos N, et al. ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS Neuro-Oncology. 20: vi13-vi13. DOI: 10.1093/Neuonc/Noy148.047 |
0.316 |
|
| 2018 |
de Groot J, Penas-Prado M, Mandel J, O’Brien B, Weathers S, Loghin M, Kamiya-Matsuoka C, Zhou S, Colen R, Hunter K, Fuller G, Huse JT, Rao G, Weinberg J, Prabhu S, ... ... Yuan Y, et al. ATIM-07. WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS Neuro-Oncology. 20: vi2-vi2. DOI: 10.1093/Neuonc/Noy148.004 |
0.329 |
|
| 2017 |
Guo B, Yuan Y. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Journal of the American Statistical Association. 112: 508-520. PMID 32863478 DOI: 10.1080/01621459.2016.1228534 |
0.37 |
|
| 2017 |
Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y. Phase I-II clinical trial design: A state-of-the-art paradigm for dose finding. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29267863 DOI: 10.1093/Annonc/Mdx795 |
0.375 |
|
| 2017 |
Pan H, Yuan Y, Xia J. A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. Journal of the Royal Statistical Society. Series C, Applied Statistics. 66: 979-996. PMID 29249839 DOI: 10.1111/Rssc.12204 |
0.627 |
|
| 2017 |
Cai C, Rahbar MH, Hossain MM, Yuan Y, Gonzales NR. A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research. Contemporary Clinical Trials Communications. 7: 11-17. PMID 29062975 DOI: 10.1016/J.Conctc.2017.05.002 |
0.387 |
|
| 2017 |
Mandel JJ, Yust-Katz S, Patel AJ, Cachia D, Liu D, Park M, Yuan Y, A Kent T, de Groot JF. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro-Oncology. PMID 29016865 DOI: 10.1093/Neuonc/Nox144 |
0.343 |
|
| 2017 |
Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. Journal of the American Statistical Association. 112: 11-23. PMID 28943681 DOI: 10.1080/01621459.2016.1176926 |
0.369 |
|
| 2017 |
Shen W, Ning J, Yuan Y, Lok AS, Feng Z. Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics. PMID 28742219 DOI: 10.1111/Biom.12750 |
0.301 |
|
| 2017 |
Ahn J, Morita S, Wang W, Yuan Y. Bayesian analysis of longitudinal dyadic data with informative missing data using a dyadic shared-parameter model. Statistical Methods in Medical Research. 962280217715051. PMID 28629259 DOI: 10.1177/0962280217715051 |
0.321 |
|
| 2017 |
Zhou H, Lee JJ, Yuan Y. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Statistics in Medicine. PMID 28589563 DOI: 10.1002/Sim.7338 |
0.37 |
|
| 2017 |
Yan F, Mandrekar SJ, Yuan Y. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28546227 DOI: 10.1158/1078-0432.Ccr-17-0220 |
0.396 |
|
| 2017 |
Chen Z, Li Z, Zhuang R, Yuan Y, Kutner M, Owonikoko T, Curran WJ, Kowalski J. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile. Plos One. 12: e0170187. PMID 28125617 DOI: 10.1371/Journal.Pone.0170187 |
0.386 |
|
| 2017 |
Wu J, Bryla C, McCoy A, Lisa B, Garren N, Siegel C, Grajkowska E, Theeler B, Park DM, Parrott T, Armstrong TS, Yuan Y, Gilbert MR. ACTR-69. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR ADULTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA AND GLIOBLASTOMA Neuro-Oncology. 19: vi15-vi15. DOI: 10.1093/Neuonc/Nox168.056 |
0.346 |
|
| 2016 |
Zang Y, Yuan Y. Optimal sequential enrichment designs for phase II clinical trials. Statistics in Medicine. PMID 27640874 DOI: 10.1002/Sim.7128 |
0.381 |
|
| 2016 |
Zhang L, Yuan Y. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials. Statistics in Medicine. PMID 27580928 DOI: 10.1002/Sim.7095 |
0.415 |
|
| 2016 |
Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27407096 DOI: 10.1158/1078-0432.Ccr-16-0592 |
0.353 |
|
| 2016 |
Murray TA, Thall PF, Yuan Y. Utility-based designs for randomized comparative trials with categorical outcomes. Statistics in Medicine. PMID 27189672 DOI: 10.1002/Sim.6989 |
0.372 |
|
| 2016 |
Yuan Y, Guo B, Munsell M, Lu K, Jazaeri A. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Statistics in Medicine. PMID 27112322 DOI: 10.1002/Sim.6971 |
0.381 |
|
| 2016 |
Iasonos A, Wages NA, Conaway MR, Cheung K, Yuan Y, O'Quigley J. Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. Statistics in Medicine. PMID 27090197 DOI: 10.1002/Sim.6966 |
0.326 |
|
| 2016 |
Yuan Y, Liu Y, Li B, Wang B, Wang S, Peng Y. Short-chain fatty acids production and microbial community in sludge alkaline fermentation: Long-term effect of temperature. Bioresource Technology. 211: 685-690. PMID 27060243 DOI: 10.1016/J.Biortech.2016.03.138 |
0.423 |
|
| 2016 |
Chu Y, Pan H, Yuan Y. Adaptive dose modification for phase I clinical trials. Statistics in Medicine. PMID 27027650 DOI: 10.1002/Sim.6933 |
0.618 |
|
| 2016 |
Pan H, Yuan Y. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Statistics in Medicine. PMID 26991076 DOI: 10.1002/Sim.6941 |
0.65 |
|
| 2016 |
Riviere MK, Yuan Y, Jourdan JH, Dubois F, Zohar S. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. Statistical Methods in Medical Research. PMID 26988926 DOI: 10.1177/0962280216631763 |
0.408 |
|
| 2016 |
Zang Y, Liu S, Yuan Y. Optimal marker-strategy clinical trial design to detect predictive markers for targeted therapy. Biostatistics (Oxford, England). PMID 26951724 DOI: 10.1093/Biostatistics/Kxw006 |
0.344 |
|
| 2016 |
Guo B, Li Y, Yuan Y. A dose-schedule finding design for phase I-II clinical trials. Journal of the Royal Statistical Society. Series C, Applied Statistics. 65: 259-272. PMID 26877554 DOI: 10.1111/Rssc.12113 |
0.418 |
|
| 2016 |
Zhou R, Scheurer ME, Gilbert MR, Bondy M, Sulman EP, Yuan Y, Liu Y, Vera E, Wendland MM, Brachman D, Bearden J, McGovern SL, Wilson SS, Judy KD, Robins HI, et al. Polymorphisms risk modeling for vascular toxicity in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Journal of Clinical Oncology. 34: 2049-2049. DOI: 10.1200/Jco.2016.34.15_Suppl.2049 |
0.316 |
|
| 2016 |
Zang Y, Lee JJ, Yuan Y. Two-stage marker-stratified clinical trial design in the presence of biomarker misclassification Journal of the Royal Statistical Society Series C-Applied Statistics. 65: 585-601. DOI: 10.1111/Rssc.12140 |
0.341 |
|
| 2016 |
Yuan X, Ji B, Yuan Y, Wu X, Zhang X. Co-scheduling of lock and water-land transshipment for ships passing the dam Applied Soft Computing Journal. 45: 150-162. DOI: 10.1016/j.asoc.2016.04.019 |
0.352 |
|
| 2015 |
Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, et al. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. Journal of Neuro-Oncology. PMID 26476729 DOI: 10.1007/S11060-015-1958-Z |
0.325 |
|
| 2015 |
Chen Z, Yuan Y, Li Z, Kutner M, Owonikoko T, Curran WJ, Khuri F, Kowalski J. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials. Contemporary Clinical Trials. 43: 133-41. PMID 26012358 DOI: 10.1016/J.Cct.2015.05.014 |
0.452 |
|
| 2015 |
DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, Yuan Y, Liu D, Goldman S, Fisher P, Rytting M, Bouffet E, Khakoo Y, Hwang EI, Foreman N, et al. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). Journal of Neuro-Oncology. 123: 85-91. PMID 25859842 DOI: 10.1007/S11060-015-1764-7 |
0.318 |
|
| 2015 |
Shen W, Ning J, Yuan Y. A direct method to evaluate the time-dependent predictive accuracy for biomarkers. Biometrics. 71: 439-49. PMID 25758584 DOI: 10.1111/Biom.12293 |
0.337 |
|
| 2015 |
Shen W, Ning J, Yuan Y. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance. Statistics in Medicine. 34: 2104-15. PMID 25756852 DOI: 10.1002/Sim.6474 |
0.441 |
|
| 2015 |
Jin IH, Huo L, Yin G, Yuan Y. Phase I trial design for drug combinations with Bayesian model averaging. Pharmaceutical Statistics. 14: 108-19. PMID 25641851 DOI: 10.1002/Pst.1668 |
0.483 |
|
| 2015 |
Guo B, Yuan Y. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts. Statistics in Medicine. 34: 1721-32. PMID 25626676 DOI: 10.1002/Sim.6443 |
0.466 |
|
| 2015 |
Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Statistics in Medicine. 34: 1681-94. PMID 25626429 DOI: 10.1002/Sim.6442 |
0.643 |
|
| 2015 |
Guo B, Zang Y, Yuan Y. A Bayesian phase I/II clinical trial design in the presence of informative dropouts Statistics and Its Interface. 8: 217-226. DOI: 10.4310/Sii.2015.V8.N2.A9 |
0.347 |
|
| 2015 |
Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Groves MD, Raizer JJ, Giglio P, Colman H, Peereboom DM, Walbert T, Avgeropoulos NG, Iwamoto FM, Chamberlain MC, Paleologos N, Fink KL, et al. Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102). Journal of Clinical Oncology. 33: 2012-2012. DOI: 10.1200/Jco.2015.33.15_Suppl.2012 |
0.34 |
|
| 2015 |
Fellman BM, Yuan Y. Bayesian optimal interval design for phase I oncology clinical trials Stata Journal. 15: 110-120. DOI: 10.1177/1536867X1501500107 |
0.409 |
|
| 2015 |
Zang Y, Liu S, Yuan Y. Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers Journal of the Royal Statistical Society. Series C: Applied Statistics. 64: 635-650. DOI: 10.1111/Rssc.12092 |
0.379 |
|
| 2015 |
Liu S, Yuan Y. Bayesian optimal interval designs for phase I clinical trials Journal of the Royal Statistical Society Series C-Applied Statistics. 64: 507-523. DOI: 10.1111/Rssc.12089 |
0.434 |
|
| 2015 |
Riviere M-, Yuan Y, Dubois F, Zohar S. A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent Journal of the Royal Statistical Society Series C-Applied Statistics. 64: 215-229. DOI: 10.1111/Rssc.12072 |
0.422 |
|
| 2015 |
Zhou R, Scheurer M, Gilbert M, Bondy M, Sulman E, Yuan Y, Liu Y, Vera-Bolanos E, Wendland M, Brachman D, Bearden J, McGovern S, Wilson S, Judy K, Robins HI, et al. EPID-33RISK MODELING FOR VASCULAR TOXICITY IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825 Neuro-Oncology. 17: v85.3-v85. DOI: 10.1093/Neuonc/Nov213.33 |
0.322 |
|
| 2015 |
Scheurer ME, Zhou R, Gilbert MR, Bondy ML, Sulman EP, Yuan Y, Liu Y, Vera-Bolanos E, Wendland MM, Brachman DG, Stieber VW, Komaki RR, Flickinger JC, Kenyon LC, Robins HI, et al. EPID-25GERMLINE POLYMORPHISMS IN MGMT INCREASE ABILITY TO MODEL TEMOZOLOMIDE (TMZ)-RELATED MYELOTOXICITY RISK IN PATIENTS WITH GLIOBLASTOMA (GBM) TREATED ON NRG ONCOLOGY/RTOG 0825 Neuro-Oncology. 17: v83.3-v83. DOI: 10.1093/Neuonc/Nov213.25 |
0.322 |
|
| 2015 |
Wu J, Puduvalli VK, Yuan Y, Armstrong T, Walker B, Upshaw C, Giglio P, Colman H, Groves MD, Raizer J, Walbert T, Tran D, Avgeropoulos N, Iwamoto F, Peereboom D, et al. ATCT-34BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB PLUS VORINOSTAT VERSUS BEVACIZUMAB ALONE IN ADULTS WITH RECURRENT GLIOBLASTOMA Neuro-Oncology. 17: v9.2-v9. DOI: 10.1093/Neuonc/Nov206.34 |
0.354 |
|
| 2014 |
Jin IH, Liu S, Thall PF, Yuan Y. Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. Journal of the American Statistical Association. 109: 525-536. PMID 25382884 DOI: 10.1080/01621459.2014.881740 |
0.402 |
|
| 2014 |
Pan H, Zhu C, Zhang F, Yuan Y, Zhang S, Zhang W, Li C, Wang L, Xia J. The continual reassessment method for multiple toxicity grades: a bayesian model selection approach. Plos One. 9: e98147. PMID 24875783 DOI: 10.1371/Journal.Pone.0098147 |
0.621 |
|
| 2014 |
Zang Y, Lee JJ, Yuan Y. Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clinical Trials (London, England). 11: 319-327. PMID 24844841 DOI: 10.1177/1740774514529848 |
0.423 |
|
| 2014 |
Riviere MK, Yuan Y, Dubois F, Zohar S. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. Pharmaceutical Statistics. 13: 247-57. PMID 24828456 DOI: 10.1002/Pst.1621 |
0.464 |
|
| 2014 |
Cai C, Liu S, Yuan Y. A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Statistics in Medicine. 33: 4017-28. PMID 24817556 DOI: 10.1002/Sim.6200 |
0.402 |
|
| 2014 |
Cai C, Yuan Y, Ji Y. A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents. Journal of the Royal Statistical Society. Series C, Applied Statistics. 63: 159-173. PMID 24511160 DOI: 10.1111/Rssc.12039 |
0.378 |
|
| 2014 |
Armstrong TS, Vera-Bolanos E, Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Aldape K, Mendoza T. At-07A Phase Ii Study Of Lapatinib And Dose-Dense Temozolomide (Tmz) For Adults With Recurrent Ependymoma: Patient Reported Outcomes (Pro) From A Cern Clinical Trial. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.7 |
0.33 |
|
| 2014 |
Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins HI, Gerstner E, Wu J, Wen P, Mikkelsen T, Armstrong T, Aldape K. AT-23 * A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL Neuro-Oncology. 16: v13-v13. DOI: 10.1093/Neuonc/Nou237.23 |
0.366 |
|
| 2013 |
Liu S, Yin G, Yuan Y. BAYESIAN DATA AUGMENTATION DOSE FINDING WITH CONTINUAL REASSESSMENT METHOD AND DELAYED TOXICITY. The Annals of Applied Statistics. 7: 1837-2457. PMID 24707327 DOI: 10.1214/13-Aoas661 |
0.463 |
|
| 2013 |
Ahn J, Liu S, Wang W, Yuan Y. Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts. Biometrics. 69: 914-24. PMID 24328715 DOI: 10.1111/Biom.12100 |
0.333 |
|
| 2013 |
Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer. 119: 2747-53. PMID 23633392 DOI: 10.1002/Cncr.28031 |
0.36 |
|
| 2013 |
Cai C, Yuan Y, Johnson VE. Bayesian adaptive phase II screening design for combination trials. Clinical Trials (London, England). 10: 353-62. PMID 23359875 DOI: 10.1177/1740774512470316 |
0.365 |
|
| 2012 |
Huo L, Yuan Y, Yin G. Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses. Bayesian Analysis (Online). 7: 1035-1052. PMID 23956811 DOI: 10.1214/12-Ba735 |
0.39 |
|
| 2012 |
Zhang G, Yuan Y. BAYESIAN MODELING LONGITUDINAL DYADIC DATA WITH NONIGNORABLE DROPOUT, WITH APPLICATION TO A BREAST CANCER STUDY. The Annals of Applied Statistics. 6: 753-771. PMID 23814631 DOI: 10.1214/11-Aoas515 |
0.513 |
|
| 2011 |
Yuan Y, Yin G. BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED DRUGS. The Annals of Applied Statistics. 5: 924-942. PMID 22375162 DOI: 10.1214/10-Aoas433 |
0.417 |
|
| 2011 |
Yuan Y, Yin G. Robust EM Continual Reassessment Method in Oncology Dose Finding. Journal of the American Statistical Association. 106: 818-831. PMID 22375092 DOI: 10.1198/Jasa.2011.Ap09476 |
0.421 |
|
| 2011 |
Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Statistics in Medicine. 30: 1218-29. PMID 21432894 DOI: 10.1002/Sim.4218 |
0.377 |
|
| 2011 |
Yuan Y, Yin G. Bayesian hybrid dose-finding design in phase I oncology clinical trials. Statistics in Medicine. 30: 2098-108. PMID 21365672 DOI: 10.1002/Sim.4164 |
0.398 |
|
| 2011 |
Lei X, Yuan Y, Yin G. Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity. Lifetime Data Analysis. 17: 156-74. PMID 20364321 DOI: 10.1007/S10985-010-9163-Z |
0.42 |
|
| 2010 |
Yuan Y, Yin G. Bayesian quantile regression for longitudinal studies with nonignorable missing data. Biometrics. 66: 105-14. PMID 19459836 DOI: 10.1111/J.1541-0420.2009.01269.X |
0.326 |
|
| 2009 |
Yin G, Yuan Y. A latent contingency table approach to dose finding for combinations of two agents. Biometrics. 65: 866-75. PMID 18759848 DOI: 10.1111/J.1541-0420.2008.01119.X |
0.415 |
|
| 2009 |
Yuan Y, Little RJ. Mixed-effect hybrid models for longitudinal data with nonignorable dropout. Biometrics. 65: 478-86. PMID 18759842 DOI: 10.1111/J.1541-0420.2008.01102.X |
0.59 |
|
| 2009 |
Yuan Y, Little RJ. Meta-analysis of studies with missing data. Biometrics. 65: 487-96. PMID 18565168 DOI: 10.1111/J.1541-0420.2008.01068.X |
0.611 |
|
| 2009 |
Yin G, Yuan Y. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials Journal of the American Statistical Association. 104: 954-968. DOI: 10.1198/Jasa.2009.Ap08425 |
0.431 |
|
| 2009 |
Yuan Y, Yin G. Bayesian dose finding by jointly modelling toxicity and efficacy as time-to-event outcomes Journal of the Royal Statistical Society: Series C (Applied Statistics). 58: 719-736. DOI: 10.1111/J.1467-9876.2009.00674.X |
0.427 |
|
| 2009 |
Yin G, Yuan Y. Bayesian dose finding in oncology for drug combinations by copula regression Journal of the Royal Statistical Society: Series C (Applied Statistics). 58: 211-224. DOI: 10.1111/J.1467-9876.2009.00649.X |
0.402 |
|
| 2008 |
Yuan Y, Yin G. Sequential continual reassessment method for two-dimensional dose finding. Statistics in Medicine. 27: 5664-78. PMID 18618901 DOI: 10.1002/Sim.3372 |
0.393 |
|
| 2007 |
Yuan Y, Little RJ. Parametric and semiparametric model-based estimates of the finite population mean for two-stage cluster samples with item nonresponse. Biometrics. 63: 1172-80. PMID 17489967 DOI: 10.1111/J.1541-0420.2007.00816.X |
0.588 |
|
| Show low-probability matches. |